To account for the fact that the engineered variants possessed reduced inherent activity compared to hLYZ, we next normalized the cell kill data to the enzymas’ relative lytic rates in the absence of inhibitor (Figure 4A, right) In the context of this correction, variant 2A was easily the most effective antibacterial treatment, having 2.5-fold greater normalized activity than hLYZ.